Publications

New Publication in Journal of Functional Biomaterials Highlights Positive Preclinical Results for Xerafuse™

A new study titled “A Pre-Set Calcium Sulfate/Hydroxyapatite Biomaterial as an Antibiotic-Eluting Bone Extender and a Carrier for BMP-2: A Pilot Study in a Rabbit Posterolateral Spinal Fusion Model” has now been published in the Journal of Functional Biomaterials. In November 2025, Moroxite AB reported positive outcomes for Xerafuse™ rhBMP-2 and Xerafuse™ Tobramycin in a preclinical spinal fusion study. We are pleased to announce that the full study—including tobramycin pha

Mar 3

Transforming spinal surgery with innovations in biologics and additive manufacturing

The synergistic integration of biologics and additive manufacturing (AM) technologies has catalyzed groundbreaking advancements in spinal...

Jun 30, 2025

Exploring an innovative augmentation strategy in spinal fusion: A novel selective prostaglandin EP4 receptor agonist as a potential osteopromotive factor to enhance lumbar posterolateral fusion

Background On-site delivery of bioactive agents facilitates enhancing the effectiveness of spinal fusion. However, the FDA-approved...

Jan 14, 2025

Co-delivery of rhBMP-2 and zoledronic acid using calcium sulfate/hydroxyapatite carrier as a bioactive bone substitute to enhance and accelerate spinal fusion

Recombinant human bone morphogenetic protein-2 (rhBMP-2) has been FDA-approved for lumbar fusion, but supraphysiologic initial burst...

Jun 28, 2024